VYNE Profile
VYNE Therapeutics Inc. is a pharmaceutical company dedicated to developing innovative therapeutics for immuno-inflammatory conditions. The company's pipeline includes several promising drug candidates targeting a range of dermatological and systemic inflammatory diseases. VYNE's focus is on advancing treatments that address unmet medical needs and improve patient outcomes in chronic inflammatory conditions.
The company's lead product candidate, FCD105, is a topical combination foam designed to treat moderate-to-severe acne vulgaris. This formulation has completed Phase III clinical trials and represents a significant advancement in the management of acne, aiming to provide effective and convenient treatment options for patients. VYNE Therapeutics is also advancing FMX114, a combination of tofacitinib, which is currently undergoing Phase IIa trials. This drug is being investigated for its efficacy in treating mild-to-moderate atopic dermatitis, offering potential relief for patients suffering from this challenging condition.
In addition to these programs, VYNE is developing VYN201, a bromodomain and extra-terminal (BET) inhibitor, which holds promise for treating various immuno-inflammatory diseases, including specific skin disorders. VYN201 aims to modulate the activity of immune cells to reduce inflammation and improve symptoms. Another key component of VYNE's pipeline is VYN202, a series of BET inhibitor compounds with selectivity for bromodomain 2. These compounds are designed to offer targeted therapeutic effects, potentially enhancing treatment options for patients with inflammatory conditions.
Formerly known as Menlo Therapeutics Inc., VYNE Therapeutics Inc. rebranded in September 2020 to better reflect its expanded focus and innovative pipeline. Founded in 2003 and headquartered in Bridgewater, New Jersey, the company continues to advance its research and development efforts to bring new, effective treatments to market. For more information about VYNE Therapeutics and its ongoing clinical programs, visit their official website.
|
